• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

    63.52 +0.46 (+0.73%)
    Streaming Delayed Price Updated: 11:21 AM EDT, Apr 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 145,349
    Open 63.21
    Bid (Size) 63.48 (100)
    Ask (Size) 63.61 (100)
    Prev. Close 63.06
    Today's Range 63.10 - 64.07
    52wk Range 47.50 - 82.22
    Shares Outstanding 142,334,900
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    1 of Wall Street’s Favorite Stock with Exciting Potential and 2 That Underwhelm
    Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
    Via StockStory
    News headline image
    3 Cash-Producing Stocks with Exciting Potential
    Free cash flow is one of the most reliable indicators of financial durability. These businesses not only generate cash but reinvest intelligently to sustain ... 
    Via StockStory

    Performance

    YTD
    -9.7%
    -9.7%
    1 Month
    +2.2%
    +2.2%
    3 Month
    -12.8%
    -12.8%
    6 Month
    -2.7%
    -2.7%
    1 Year
    +4.4%
    +4.4%

    More News

    Read More
    News headline image
    2 Small-Cap Stocks with Solid Fundamentals and 1 We Ignore
    Via StockStory
    News headline image
    1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off
    Via StockStory
    Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Value Investment Case ↗
    Via Chartmill
    Halozyme Therapeutics Inc (NASDAQ:HALO) Reports Mixed Q4 2025 Results with Revenue Beat and Unexpected Loss ↗
    Via Chartmill
    HALOZYME THERAPEUTICS INC (NASDAQ:HALO): A GARP Stock with Strong Growth and Reasonable Valuation ↗
    Via Chartmill
    Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Growth and Technical Setup ↗
    Via Chartmill
    News headline image
    Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    2 Reasons to Like HALO (and 1 Not So Much)
    Via StockStory
    Topics Stocks
    News headline image
    Halozyme (HALO) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales
    Via StockStory
    News headline image
    Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know
    Via StockStory
    Topics Economy
    News headline image
    3 Small-Cap Stocks with Solid Fundamentals
    Via StockStory
    Topics Government
    News headline image
    3 Growth Stocks Set to Flourish
    Via StockStory
    News headline image
    A Look Back at Therapeutics Stocks’ Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Q3 Earnings Highs And Lows: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    HALO Stock Edges Up 3% On Upbeat Multi-Year Revenue Guidance, Surf Bio Acquisition ↗
    Via Stocktwits
    News headline image
    Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR)
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Q3 Rundown: Amgen (NASDAQ:AMGN) Vs Other Therapeutics Stocks
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗
    Via The Motley Fool
    Topics ETFs Intellectual Property World Trade
    News headline image
    Reflecting On Therapeutics Stocks’ Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX)
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Unpacking Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty ↗
    Via The Motley Fool
    News headline image
    Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks
    Via StockStory
    Topics Artificial Intelligence

    Frequently Asked Questions

    Is Halozyme Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Halozyme Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Halozyme Therapeutics, Inc. - Common Stock trade on?
    Halozyme Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Halozyme Therapeutics, Inc. - Common Stock?
    The ticker symbol for Halozyme Therapeutics, Inc. - Common Stock is HALO on the Nasdaq Stock Market
    What is the current price of Halozyme Therapeutics, Inc. - Common Stock?
    The current price of Halozyme Therapeutics, Inc. - Common Stock is 63.52
    When was Halozyme Therapeutics, Inc. - Common Stock last traded?
    The last trade of Halozyme Therapeutics, Inc. - Common Stock was at 04/30/26 11:21 AM ET
    What is the market capitalization of Halozyme Therapeutics, Inc. - Common Stock?
    The market capitalization of Halozyme Therapeutics, Inc. - Common Stock is 9.04B
    How many shares of Halozyme Therapeutics, Inc. - Common Stock are outstanding?
    Halozyme Therapeutics, Inc. - Common Stock has 9B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.